CaliPharms Debt to Equity

The latest debt-to-equity ratio for KGET is -0.03. That is below the Industrials sector average of 1.28. Investors often review this figure alongside CaliPharms's historical trend and sector peers before judging valuation or financial health.

Against Industrials companies, KGET currently prints -0.03 for debt-to-equity ratio, while the sector average sits near 1.28. That is roughly 102.0% below the sector mean. Large gaps often invite a closer look at CaliPharms's growth, margins, and balance sheet.

A debt-to-equity ratio of -0.03 for CaliPharms is not 'good' or 'bad' on its own. Compare it with the peer average (1.28) and with KGET's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting KGET's debt-to-equity ratio (-0.03), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack CaliPharms's debt-to-equity ratio against similar Industrials names. You can also browse sector and industry screens on Stockcircle for a broader set of Industrials companies and their key multiples and fundamentals.